MedTrace Logo

Evaluation of Fibrin Structure Marker in Cancer Patients Treated and Not Treated With LMWH

NCT02552381 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 389

Last updated 2020-01-07

No results posted yet for this study

Summary

The purpose of the study is to assess the fibrin structure marker in the plasma of cancer patients, treated or not treated with LMWH at prophylactic or therapeutic doses, in order to determine the venous thromboembolic risk. The occurrence of thromboembolic events in patients without treatment and in patients under LMWH treatment will be recorded, depending on the location and type of cancer, metastases, and treatment of cancer.

Conditions

  • Malignant Tumor

Interventions

OTHER

Fibrin Structure

Modifications of Fibrin Structure in patients who have developed VTE in comparison with patients without VTE.

Sponsors & Collaborators

  • Hôpital Louis Mourier

    collaborator OTHER

  • Hopital Lariboisière

    collaborator OTHER

  • Diagnostica Stago R&D

    lead INDUSTRY

Principal Investigators

  • Isabelle Mahe, MD, PhD · Université of Paris 7 - Paris Diderot

  • Geneviève Contant, PhD · Diagnostica Stago

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2019-12-20
Completion
2019-12-20

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02552381 on ClinicalTrials.gov